Drug Trial Radar · NCT03985982
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)
Last checked: Nov 20, 2026Latest source record: Jun 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
410
Actual
Start
Apr 29, 2019
Primary completion
Dec 4, 2019
Study completion Dec 22, 2020
Sponsor
- Lead sponsor
- Croma-Pharma GmbHIndustry
- Sponsor type
- Industry
- First posted
- Jun 14, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.
Conditions
- Glabellar Frown Lines
Interventions
Botulinum Toxin ADrug
Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area
PlaceboDrug
injection, sodium chloride 0.9 % divided in five 0.1 mL i.m injections into the glabellar area
Botulinum Toxin ADrug
Injection, 20 Units divided in five 0.1 mL i.m injections into the glabellar area in up to 3 treatment cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the Investigators´ and the Subjects´ In-clinic Assessments.Time frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tennessee Clinical Research Center
Nashville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.